AUGUST 18, 2021
Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy.
MARCH 18, 2021
Roche launches DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research
JANUARY 11, 2021
New digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer, help drive individual patient treatment strategies.
AUGUST 28, 2020
Helps identify triple-negative breast cancer (TNBC) patients most likely to benefit from treatment with Tecentriq plus chemotherapy.
JUNE 29, 2020
FDA approves Roche’s new VENTANA HER2 Dual ISH test as companion diagnostic to identify breast cancer patients eligible for targeted therapy.